TRIB - Trinity Biotech Announces Appointment of A New CFO | Benzinga
DUBLIN, July 09, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the appointment of Louise Tallon as Chief Financial Officer ("CFO"). Louise will join Trinity Biotech in August 2024. Des Fitzgerald, who has acted as interim CFO since December 2023 will continue as interim CFO until late July 2024.
Commenting on the appointment, John Gillard, CEO of Trinity Biotech plc, said "We are delighted to welcome Louise, who brings extensive experience in transformation and growth within a dynamic environment. This skill set, combined with her extensive experience in the life sciences product commercialisation industry, will elevate the continued development of the organisation as we continue to deliver on our corporate strategy of delivering our comprehensive transformation plan and introducing our next generation continuous glucose monitor, or CGM, to global markets. With the CFO transition we also reiterate our financial guidance and intend to achieve approximately $20 million of annualized run-rate EBITDASO1 on annualized revenues of approximately $75 million by Q2 2025."
Louise Tallon responded, "I'm excited to join the Trinity Biotech team and look forward to contributing to its exciting vision to become a highly profitable organisation, intent on executing its development and launch of a next generation CGM device."
Louise is currently Head of Group Finance at Inizio, a leading global commercialisation partner in pharmaceuticals. Prior to this, she had a 16-year career with UDG Healthcare plc, where she held a number of senior finance roles of increasing responsibility. Over her 19-year career in the life sciences industry, as a transformative leader, Louise ...